Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 3 1

Status

Recruiting 2Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1NIH 1NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 47Lymphoid 38Other hematologic neoplasm 22CNS 7Sarcoma 6Genitourinary 6Endocrine 5Plasma cell 3Dermatologic 3Other solid neoplasm 2NET 2Myeloid 2Head & Neck 2Gynecologic 1Gastrointestinal 1

Conditions

Neuroendocrine Tumors 2Carcinoma, Neuroendocrine 2Somatostatinoma 1Neuroendocrine Neoplasms 1Extrapulmonary Neuroendocrine Cancer 1

Interventions

Magnetic Resonance Spectroscopy 15Specimen Handling 14lutetium Lu 177 dotatate 13Nivolumab 11cabozantinib 10Everolimus 9pembrolizumab 8gallium Ga 68 dotatate 7Ipilimumab 6Cisplatin 6Carboplatin 6Etoposide 5trametinib 4olaparib 4lenvatinib 4X-Rays 4Lutetium-177 4CTLA-4 Antigen 4fluorodopa F 18 3dabrafenib 3cemiplimab 3Surveys and Questionnaires 3Phantoms, Imaging 3Immunoglobulin G 3Fluorodeoxyglucose F18 3Disulfides 3Cyclophosphamide 3Blood Specimen Collection 3177Lu-octreotide, DOTA(0)-Tyr(3)- 3selpercatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Etoposide × Endocrine × 90 days × Clear all
NCT06132113 2026-05-27

DAREONā„¢-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers

Boehringer Ingelheim

Phase 1 Recruiting
55 enrolled
Endocrine

Neuroendocrine Neoplasms

NCT06406465 2026-05-27

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
60 enrolled
EndocrineNET

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT07544654 2026-05-27

DAREONĀ®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

Boehringer Ingelheim

Phase 3 Not yet recruiting
390 enrolled
Endocrine

Extrapulmonary Neuroendocrine Cancer

NCT02595424 2026-05-01

Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
67 enrolled 13 charts
Endocrine

Somatostatinoma, Carcinoma, Neuroendocrine

NCT02402920 2026-03-10

Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer

M.D. Anderson Cancer Center

Phase 1 Completed
83 enrolled 13 charts
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚔